Background: Diagnosis and management of neuropathic cancer pain (NCP) is diffi cult and complicated. This study investigated current practice in the diagnosis and management of NCP and its impact on quality of life (QoL). Methods: Patients with cancer pain with visual analogue scales (VAS) =1 from 28 hospitals in Korea were enrolled in this cross-sectional observational study. If the patient obtained a score =4 from neuropathic pain diagnostic questionnaire (DN4), he/ she was diagnosed with NCP. The clinical characteristics, pain severity measured by Brief Pain Inventory-Short Form (BPI-SF), and the QoL measured by EuroQoL EQ-5D Health Questionnaire were evaluated. Results: Among 1,505 enrolled patients, 885 patients (58.8%) had moderate to severe pain (VAS=4). Neuropathic cancer pain (when DN4 =4) was identified in 556 patients (36.9%). Among those NCP patients, 254 patients (45.7%) were treated with NCP-targeted therapies (administering opioid or non-opioids analgesics with adjuvant analgesics). Among entire patients, opioids were used in 1,005 patients (66.8%) and 205 patients (13.6%) were not prescribed any analgesic. Anti-depressants and anti- convulsants were prescribed for 91 (6.0%) and 349 (23.2%) patients respectively. Patients with NCP had more severe pain and their pain interference level with daily living was higher than those without NCP. The QoL measured by EQ-5D index score was signifi cantly worse in patients with NCP than those without NCP (Table 1). Conclusions: This large-scaled survey shows that NCP has deteriorative effect on pain and QoL in patients having cancer pain. Current status of management for cancer pain is not satisfactory including NCP in Korea. *This study was partially presented at the MASCC/ISOO International symposium on supportive care in cancer, 26 - 28 June 2014, Miami, USA.